Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Galectin-9 (Gal-9) is a potential biomarker for renal disease; however, its role in chronic kidney disease (CKD) progression remains underexplored. In this study, we investigated the association between plasma Gal-9 levels and kidney histopathology, as well as its prognostic value for major adverse renal events (MARE) in patients with biopsy-proven kidney disease.
A prospective cohort study was conducted involving 366 individuals who underwent renal biopsy at a tertiary medical center between October 1, 2018, and March 31, 2023. Plasma Gal-9 levels were measured, and renal chronicity was evaluated using the modified Mayo Clinic Chronicity Score (MCCS). Logistic and Cox regression analyses were performed to assess the associations of Gal-9 with individual histopathologic lesions and MARE, defined as a ≥40% decline in eGFR, initiation of dialysis, or death from renal or cardiovascular causes.
Elevated plasma Gal-9 levels were significantly correlated with higher MCCS and proteinuria, and with lower eGFR. High Gal-9 levels were associated with multiple chronic lesions but remained independently associated only with mesangial expansion after multivariable adjustment. The median follow-up duration was 1.8 years, during which 133 of the 366 patients experienced MARE. Cox regression analysis showed that plasma Gal-9 was independently associated with these events, with an adjusted hazard ratio of 2.36 (95% CI: 1.25–4.44) for tertile 3 versus tertile 1.
In summary, elevated plasma Gal-9 levels are associated with mesangial expansion and may predict adverse kidney outcomes in patients with CKD of various etiologies.
